Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs - Wikidata - wikimedia - TriplyDB

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

http://www.wikidata.org/entity/Q24630309

about

Genome-wide association study of d-amphetamine response in healthy volunteers identifies putative associations, including cadherin 13 (CDH13)Pharmacogenomics discovery and implementation in genome-wide association studies era When drug discovery meets web search: Learning to Rank for ligand-based virtual screening Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics Progress in understanding the genomic basis for adverse drug reactions: a comprehensive review and focus on the role of ethnicity Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain Genotype-based ancestral background consistently predicts efficacy and side effects across treatments in CATIE and STAR*D BCL9 and C9orf5 are associated with negative symptoms in schizophrenia: meta-analysis of two genome-wide association studies Schizophrenia.Genetic regulation of Nrxn1 [corrected] expression: an integrative cross-species analysis of schizophrenia candidate genes Pharmacogenetics of antipsychotics.Genetic determinants of lipid traits in diverse populations from the population architecture using genomics and epidemiology (PAGE) study DNA methylation changes in the postmortem dorsolateral prefrontal cortex of patients with schizophrenia.Improving metabolic and cardiovascular health at an early psychosis intervention program in vancouver, Canada Replication of SULT4A1-1 as a pharmacogenetic marker of olanzapine response and evidence of lower weight gain in the high response group.Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial Antipsychotic drugs and obesity.Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study.The impact of clinical heterogeneity in schizophrenia on genomic analyses SOX5 is a candidate gene for chronic obstructive pulmonary disease susceptibility and is necessary for lung development.Horizons of psychiatric genetics and epigenetics: where are we and where are we heading?Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine Genome-wide association studies in Africans and African Americans: expanding the framework of the genomics of human traits and disease.Genome-wide pharmacogenomic study of citalopram-induced side effects in STAR*D.Pharmacogenetics of antipsychotics: recent progress and methodological issues.Genome-Wide Meta-Analysis of Longitudinal Alcohol Consumption Across Youth and Early Adulthood.Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.Mechanisms and Disease Associations of Haplotype-Dependent Allele-Specific DNA Methylation Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients.Single nucleotide polymorphisms in the REG-CTNNA2 region of chromosome 2 and NEIL3 associated with impulsivity in a Native American sample.Silencing of the Drosophila ortholog of SOX5 in heart leads to cardiac dysfunction as detected by optical coherence tomography Genotypic variation in the SV2C gene impacts response to atypical antipsychotics the CATIE study.Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.Pharmacogenetics of response to antipsychotics in patients with schizophrenia.Pharmacogenetics in psychiatry: translating research into clinical practice.Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia.

P2860

Q21134099-8A9E365B-2BC1-4C73-A290-E2277B8732DD Q27001573-9B20DD38-F6BE-4D9C-B241-7A0590B2AE6A Q27902275-85B6AA22-86A9-433A-A5EB-7B446535B0F5 Q28079065-50E8CEB4-11A8-44CD-9E53-C7F20D3C5D97 Q28083100-0951C1F6-A77F-4519-96C4-48E6AC3DF5A1 Q28266158-2FDE7CF3-8687-487E-92EA-B6A3740E0EB9 Q28486019-44D92256-C7D7-41F2-873A-CD4F7A994780 Q28943394-8B2FEEDE-9B21-44D5-A101-34D485E1C984 Q30251961-8A0A5646-62B5-42F2-90E6-53FF49C8AC5D Q30468815-DDCAD39A-7032-4A36-8D17-A9F8B82AB858 Q33836837-D9F160AA-1EB5-4D52-9DE8-A815C737D428 Q33954461-D1B47D08-4059-4243-9C97-8DAE7A019B73 Q34088110-210B7A66-6F4C-43AF-B4BA-4D9D39E5FCF5 Q34139645-C7EFD41B-6064-4ACC-AF18-22D61324ACBA Q34155219-83BB1CBB-6633-4DC0-B7B6-782C585C399C Q34229109-87A3ADBE-167D-4ECE-B0B1-F2660168CD11 Q34644655-B63855D3-B7FF-44ED-B296-929EAFFDACCA Q34648940-D1AD25F1-48E0-4B93-9F2E-E1733B0C9991 Q34676533-F1845A53-6800-4D0F-B32B-03C2D9023FE2 Q34955404-4084ECF6-EA70-4279-971A-C6B2CF773CFC Q35019791-2908B0F0-2CE4-4EFE-AD9D-FD7683574DC6 Q35107672-C093CA0C-0E42-4AF1-8B4F-FA86D85A369F Q35177686-02701516-5AE3-48AD-BC81-55B5247A5E00 Q35375788-09227128-A0EC-4767-B63F-48EA030A5F8D Q35565624-A730D414-1963-464B-B7D2-774438760525 Q36135959-5E9C0639-7EE5-440F-B1CE-C3FD9C9FDE16 Q36539833-BEF1FEFA-B7B8-419C-96DD-8A6408AC8D5A Q36604310-2896F38F-E127-4F10-ACEF-454A13D9486E Q36702588-C7A57856-287D-44D0-A9FE-C9F72090B200 Q36891490-2691FB05-E045-4EFB-B9E4-EA1303D05AE5 Q36956632-36E2AE3E-1289-4E07-88B5-B4E13FFF3FFA Q37016538-B03524B3-A69A-41CA-8457-E1EFC10A5B6B Q37072122-194D1724-9A4B-4B38-812E-11B3A2B7EC5E Q37111971-A38C8C86-9553-463A-AB5E-06F635F101B6 Q37353278-D0F4B458-1933-4A99-BC4F-1D0BAB7386FD Q37581282-8BC8CFC4-19B6-4418-91C0-E42F67BC2F94 Q37926893-F6007E49-624B-4190-BD57-97FF505BC7E0 Q37952823-C742E787-D96F-4949-A46A-DC5B32BAC23D Q37956206-869CA1E4-9C68-4B66-993A-F14E0BD5F0AD Q37960512-0838D8C7-F9B5-48FE-AFB0-E6D0295DE08B

P2860

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

http://www.wikidata.org/entity/Q24630309

description

2011 nî lūn-bûn

@nan

2011 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մարտին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

@ast

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

@en

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

@nl

type

label

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

@ast

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

@en

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

@nl

prefLabel

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

@ast

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

@en

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

@nl

P1433

Q24630309-DEC23905-4DAE-46A3-90D4-F33A2010C9FB

P1476

Q24630309-BC6916C1-3BA3-4DD5-94E3-F507A8CD6E17

P2093

Q24630309-231A353E-9EB6-4658-B82F-8144D34EE4BF

Q24630309-2B143B00-0C6B-4480-8558-F418622121EF

Q24630309-3B8F001E-88C7-4FC2-8ADD-76A724BDF0C4

Q24630309-590A9879-8D71-4331-99DC-1BCEEF582E17

Q24630309-5B1B72F3-0427-46A6-80D5-BCB68AC3A4DA

Q24630309-63474839-88EF-49D2-8316-28D00CAFBBF9

Q24630309-A89469E9-24D5-439F-9B8E-B60D603E090A

Q24630309-AD8BDFED-F85D-4996-8935-D3F69D2DFCAB

Q24630309-AEC55A54-6693-4F26-89D4-56199C5F341F

P2860

Q24630309-0482314B-01A8-47CE-BD87-156B787B37D2

Q24630309-12827A90-7EB8-4E81-B12A-B128E2EBD0C6

Q24630309-153A06FA-B98F-46B5-A039-D8F3D61C53B1

Q24630309-157B898A-C3EB-4DBE-9249-A5A47FFDA0E5

Q24630309-1DA13D48-63DC-4DCA-A4EE-56E304BFD096

Q24630309-20FCC437-D73F-43FC-97EE-0C69C832B89E

Q24630309-21E37808-8819-4D1F-81EB-CA2120DE7817

Q24630309-237C579F-6EF5-4EDB-86C8-6FB3DDD5EE84

Q24630309-290C150B-2776-455A-8F72-C26E5975C2FB

Q24630309-38CA4366-DAB4-41A6-A259-6C6192CBD63A

P2888

Q24630309-FEBB0FB4-FDCA-48EE-9921-480FEAF8E2A3

P304

Q24630309-822D3299-02CE-44E9-9615-BCE7364985AE

P31

Q24630309-69944B3B-0B78-4C89-85A1-8A7D4018A0B7

P3181

Q24630309-7CA82178-E86C-4F99-83FA-BCF01C951DF4

P356

Q24630309-8CBB6CCD-7ECD-439A-A228-3EFB0A1BCC2B

P407

Q24630309-933EB3D1-DD5B-460A-81C5-6E7B31FF52EB

P433

Q24630309-AD3A8E83-AA9E-4777-8B7A-138916019A6A

P478

Q24630309-C56C8E50-0F7A-41AE-9682-9C9B7A759E7A

P50

Q24630309-3CF0DA94-776C-4ED5-B50E-04FACCC55CCC

Q24630309-70B8957D-5DD2-4AB5-B0A3-EBCF7C2346F7

Q24630309-B6C4855C-D8BA-4DCF-81A1-B95EB555A635

P577

Q24630309-D8DF6F0F-61DC-4118-A24E-37EFAB780200

P5875

Q24630309-E074BDE2-1FE1-4C97-B027-F3D13BEC32B6

P6179

Q24630309-40DA9830-FAB5-4309-91A4-A0D382891853

P698

Q24630309-A6670A11-4A0C-450B-868C-B60E2DEBCE63

P921

Q24630309-88394237-0273-4F62-A672-BDB9B087851E

P932

Q24630309-6374C582-7856-42A0-9BCC-92A3793F6123

P3181

P356

P1433

Molecular Psychiatry

P1476

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs

@en

P2093

D E Adkins

http://www.w3.org/2001/XMLSchema#string

D Perkins

http://www.w3.org/2001/XMLSchema#string

E J C G van den Oord

http://www.w3.org/2001/XMLSchema#string

J A Lieberman

http://www.w3.org/2001/XMLSchema#string

J Bukszár

http://www.w3.org/2001/XMLSchema#string

J P McEvoy

http://www.w3.org/2001/XMLSchema#string

P F Sullivan

http://www.w3.org/2001/XMLSchema#string

P Jia

http://www.w3.org/2001/XMLSchema#string

Z Zhao

http://www.w3.org/2001/XMLSchema#string

P2860

Genome-wide association scan meta-analysis identifies three Loci influencing adiposity and fat distribution

Three-amino acid extension loop homeodomain proteins Meis2 and TGIF differentially regulate transcription

Sequence similarities between a novel putative G protein-coupled receptor and Na+/Ca2+ exchangers define a cation binding domain

Very large G protein-coupled receptor-1, the largest known cell surface protein, is highly expressed in the developing central nervous system

Molecular cloning, complementary deoxyribonucleic acid structure and predicted full-length amino acid sequence of the hormone-inducible regulatory subunit of 3'-5'-cyclic adenosine monophosphate-dependent protein kinase from human testis

Mutations in the VLGR1 gene implicate G-protein signaling in the pathogenesis of Usher syndrome type II

Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis

Variants in MTNR1B influence fasting glucose levels.

Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia

Scientific and consumer models of recovery in schizophrenia: concordance, contrasts, and implications

P2888

P304

321-332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2650565

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/MP.2010.14

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Joseph L. McClay

P577

2010-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

41657341

http://www.w3.org/2001/XMLSchema#string

P6179

1048246833

http://www.w3.org/2001/XMLSchema#string

P698

20195266

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

P932

2891163

http://www.w3.org/2001/XMLSchema#string